JA
ABBV icon

JVL Associates’s AbbVie ABBV Stock Holding History

JVL Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Sell
1,180
-20
-2% -$4.3K 0.08% 59
2026
Q1 		$261K Buy
1,200
+54
+5% +$12K 0.09% 55
2025
Q4 		$262K Sell
1,146
-2
-0.2% -$456 0.09% 52
2025
Q3 		$266K Buy
1,148
+2
+0.2% +$407 0.09% 54
2025
Q2 		$213K Buy
1,146
+29
+3% +$5.39K 0.08% 63
2025
Q1 		$234K Sell
1,117
-48
-4% -$9.33K 0.09% 54
2024
Q4 		$207K Buy
1,165
+64
+6% +$11.8K 0.08% 55
2024
Q3 		$217K Buy
+1,101
New +$205K 0.08% 54

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JVL Associates's ABBV Position: Q2 2026 in Review

JVL Associates reduced its AbbVie (ABBV) stake by 1.7% in Q2 2026, selling an estimated $4.3K and leaving 1,180 shares worth $297K. The position accounts for 0.08% of the portfolio, ranked #59.

JVL Associates first reported a position in ABBV in Q3 2024 and has held it in 8 quarters since. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • JVL Associates held 1,180 shares of AbbVie worth $297K as of Q2 2026.
  • JVL Associates sold 20 AbbVie shares in Q2 2026, an estimated $4.3K.
  • AbbVie made up 0.08% of JVL Associates's portfolio in Q2 2026, its #59 holding.
  • JVL Associates first reported a position in AbbVie in Q3 2024 and has held it in 8 quarters since.
  • 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on JVL Associates's 13F filing for Q2 2026, filed 6 Jul 2026.